IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 357 -3.18%
12 Feb - close price
iolcp.com BSE: 524164 NSE: IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Business Segments

Website BSE NSE
  • Market Cap ₹ 2,094 Cr.
  • Current Price ₹ 357
  • High / Low ₹ 538 / 331
  • Stock P/E 21.5
  • Book Value ₹ 283
  • Dividend Yield 1.40 %
  • ROCE 12.2 %
  • ROE 8.61 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 17.6%
  • Promoter holding has increased by 4.43% over last quarter.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
572 565 541 523 587 563 545 520 504 502 526 523
527 509 510 481 492 491 481 476 454 451 484 476
Operating Profit 45 56 32 43 95 73 64 44 50 51 42 47
OPM % 8% 10% 6% 8% 16% 13% 12% 9% 10% 10% 8% 9%
7 5 5 7 9 7 7 8 8 7 6 4
Interest 2 3 4 5 5 4 4 4 3 2 4 4
Depreciation 11 11 11 12 12 14 16 16 16 17 18 19
Profit before tax 39 47 22 33 87 61 51 32 37 40 26 28
Tax % 23% 26% 28% 28% 26% 25% 26% 28% 26% 24% 26% 26%
30 35 16 24 65 46 38 23 28 30 19 21
EPS in Rs 5.07 5.91 2.71 4.05 11.03 7.81 6.45 3.93 4.70 5.11 3.26 3.50
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 TTM
2,184 2,217 2,133 2,055
1,925 1,991 1,902 1,866
Operating Profit 259 226 231 189
OPM % 12% 10% 11% 9%
17 25 30 25
Interest 8 16 16 14
Depreciation 43 46 63 70
Profit before tax 225 189 182 130
Tax % 25% 26% 26%
168 139 134 97
EPS in Rs 28.56 23.70 22.90 16.57
Dividend Payout % 14% 17% 22%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -7%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -43%
Stock Price CAGR
10 Years: 24%
5 Years: 13%
3 Years: -3%
1 Year: -12%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 59 59 59 59
Reserves 1,334 1,449 1,553 1,601
44 80 33 128
526 435 600 477
Total Liabilities 1,962 2,022 2,244 2,265
561 752 933 1,012
CWIP 105 90 101 122
Investments 2 20 20 21
1,294 1,161 1,190 1,111
Total Assets 1,962 2,022 2,244 2,265

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024
93 122 290
-121 -120 -191
-2 -4 -92
Net Cash Flow -29 -2 6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024
Debtor Days 79 83 81
Inventory Days 95 77 111
Days Payable 95 74 123
Cash Conversion Cycle 79 86 69
Working Capital Days 78 86 76
ROCE % 14% 12%

Shareholding Pattern

Numbers in percentages

3 Recently
Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
43.69% 43.69% 43.69% 43.69% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 52.62%
3.14% 2.50% 2.41% 2.37% 2.43% 3.54% 2.33% 2.18% 1.40% 1.39% 1.63% 1.49%
0.04% 0.04% 0.05% 0.16% 0.23% 0.25% 0.35% 0.36% 0.29% 0.09% 0.07% 0.08%
53.13% 53.77% 53.84% 53.78% 49.15% 48.02% 49.12% 49.27% 50.11% 50.34% 50.11% 45.81%
No. of Shareholders 1,46,4371,48,9071,45,6921,43,3271,40,1771,26,0041,35,3971,34,2351,30,0031,28,6891,25,9791,26,701

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls